Biomedical subjects

Diane S Berson

Publications and source records attributed to Diane S Berson.

4 recordsLinked to original sources

PubMed2006

Cosmeceuticals.

The aging population and a desire to maintain a youthful appearance have propelled the recent surge in the U.S. cosmeceuticals market. The rapidly growing number of products claiming to diminish fine lines and wrinkles, decrease redness, smooth texture, and fade discoloration has lead to much confusion and misinformation among dermatologists and consumers alike. Cosmeceuticals can be a useful adjunct to prescription medications and office procedures. Therefore, it behooves us as dermatologists to understand the science behind these products to better educate ourselves and our patients. We present an update of the following categories of cosmeceuticals: antioxidants, growth factors, peptides, anti-inflammatories/botanicals, polysaccharides, and pigment-lightening agents.

Cosmetic Techniques↗

PubMed2006

Topical therapies for rosacea.

Therapeutic options for rosacea include topical agents, oral therapies, laser and light treatments, and surgical procedures. Topical therapies play a critical role in the treatment of patients with papulopustular rosacea and erythematotelangiectatic rosacea, and have the ability to effectively minimize certain manifestations of the disease, including papules, pustules, and erythema. The 3 primary agents for the topical treatment of rosacea are metronidazole, azelaic acid, and sodium sulfacetamide-sulfur. Each of these therapies is approved for the treatment of rosacea and has been validated by multiple studies. Additional topical therapies including benzoyl peroxide, clindamycin, retinoids, topical steroids, calcineurin inhibitors, and permethrin are not approved for the treatment of rosacea and play variable roles in the management of this condition.

Administration, Topical↗

PubMed2004

Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.

BACKGROUND: Topical retinoids are one of the most effective classes of topical drugs used to treat acne vulgaris. The effects of the gel formulation of the topical retinoid tazarotene have been widely reported, but few data on the cream formulation are available. OBJECTIVE: The primary aim of the 2 studies reported in this article was to determine the effects of tazarotene 0.1 % cream in patients with facial acne vulgaris. METHODS: Two randomized, double-blind, parallel-group studies were performed. The first was conducted at 14 investigational sites across the United States, and the second took place at 15 sites, with 5 of these providing blood samples for analysis of tazarotenic acid. In both studies, patients aged > or =12 years with facial acne vulgaris were randomized to receive tazarotene or vehicle cream QD for 12 weeks. Lesion counts (noninflammatory, inflammatory, and total) and overall clinical and global assessments were made at weeks 0 (baseline), 4, 8, and 12. Adverse events (AEs) were monitored throughout the study In one of the studies, therapeutic drug monitoring was performed at weeks 4 and 8 in members of the study population who gave consent for blood withdrawal. RESULTS: Eight hundred forty-seven patients were enrolled in the 2 studies (430 males, 417 females; mean age,19 years; age range, 11-52 years [1 patient was entered into the study at age 11 years, in violation of the protocol]). At 12 weeks, the median percentage changes from baseline in all 3 lesion counts were significantly lower with tazarotene than with vehicle (all, P < 0.001), as were the overall clinical and global responses (both, P < 0.001). Treatment-related AEs whose incidence was higher with tazarotene than with vehicle included desquamation, dry skin, erythema, a burning sensation on the skin, and skin irritation (all, P < 0.001) and pruritus (P < 0.01); most (83%-98%) were mild or moderate. Systemic exposure to tazarotenic acid was limited (mean, <0.1 ng/mL) and did not increase with time. CONCLUSIONS: In these 2 studies in adolescent and adult patients with facial acne vulgaris, tazarotene 0.1%cream QD for 12 weeks was effective and well tolerated. Systemic exposure to tazarotenic acid was limited.

Acne Vulgaris↗

PubMed2003

Current concepts in the treatment of acne: report from a clinical roundtable.

Acne vulgaris is the most common skin disorder in the United States, affecting approximately 17 million people. This figure includes 80% of all persons between the ages of 11 and 30 years, regardless of race, ethnicity, or gender (Kraning and Odland, 1979). Acne has a significant economic and social impact on doctor visits, medications, and absenteeism, as well as in the negative effect it can have on self-image and outlook, especially during the emotionally critical period of adolescence. Persons with acne may think of themselves as unworthy and socially unacceptable. Severe acne may lead to scarring and disfigurement, aggravating the already present psychosocial aspects of this condition. Because of the multifactorial nature of acne, current treatment options aim to modify one or more of its pathogenic factors. Clinical experience has shown that combination therapies, which affect multiple aspects of pathophysiology, are most likely to achieve this goal and help in its long-term management and resolution.

Acne Vulgaris↗